Commercial-stage, biopharmaceutical company HUTCHMED (China) Limited (Nasdaq:HCM)(AIM:HCM)(HKEX:13) and Innovent Biologics, Inc. (HKEX:1801), a biopharmaceutical company, on Tuesday jointly announce New Drug Application, (NDA) acceptance in China for fruquintinib combination with sintilimab in advanced endometrial cancer, granted Priority Review after Breakthrough Therapy designation in July 2023.
This marks the first regulatory filing for fruquintinib in combination with a leading immune checkpoint inhibitor. The NDA targets patients with advanced endometrial cancer who are not eligible for curative surgery or radiation.
The submission is based on data from FRUSICA-1, a Phase II study evaluating the combination's efficacy and safety. Primary endpoints include objective response rate, with secondary endpoints covering various clinical and pharmacokinetic assessments. Breakthrough Therapy designation was granted due to the combination's potential in addressing an unmet medical need with significant clinical advantages. Fruquintinib, a selective oral VEGFR inhibitor, shows promise in inhibiting tumor angiogenesis with enhanced selectivity and sustained target inhibition, potentially expanding its utility in combination therapies.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration